Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -16% Improvement Relative Risk Ventilation 19% Severe case -3% Hospitalization 4% Antiandrogens for COVID-19  Shah et al.  Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective 465 patients in the USA (March - May 2020) Higher mortality with antiandrogens (not stat. sig., p=0.59) c19early.org Shah et al., JNCI Cancer Spectrum, May 2022 Favors antiandrogen Favors control

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

Shah et al., JNCI Cancer Spectrum, doi:10.1093/jncics/pkac035
May 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
5th treatment shown to reduce risk in August 2020
 
*, now known with p = 0.000000043 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 465 prostate cancer patients, showing no significant difference in COVID-19 outcomes with ADT.
risk of death, 16.0% higher, HR 1.16, p = 0.59, treatment 148, control 317.
risk of mechanical ventilation, 19.0% lower, HR 0.81, p = 0.73, treatment 148, control 317.
risk of severe case, 3.0% higher, HR 1.03, p = 0.91, treatment 148, control 317.
risk of hospitalization, 4.0% lower, HR 0.96, p = 0.90, treatment 148, control 317.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shah et al., 12 May 2022, retrospective, USA, peer-reviewed, median age 71.0, 22 authors, study period 1 March, 2020 - 31 May, 2020. Contact: william.oh@mssm.edu.
This PaperAntiandrogensAll
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
MD Neil J Shah, MD Vaibhav G Patel, DrPD Xiaobo Zhong, MD Luis Pina, MD Jessica E Hawley, MD Emily Lin, MD Benjamin A Gartrell, MD Victor Adorno Febles, MD David R Wise, MD Qian Qin, BA George Mellgard, PhD Himanshu Joshi, MD Jones T Nauseef, MD David A Green, MD Panagiotis J Vlachostergios, MD Daniel H Kwon, MD Franklin Huang, MD Bobby Liaw, MD Scott Tagawa, MD Philip Kantoff, MD Michael J Morris, MD William K Oh
JNCI Cancer Spectrum, doi:10.1093/jncics/pkac035
Background: TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood. Methods: We performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided. Results: We identified 465 PCa patients (median age ¼ 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] ¼ 1.16, 95% confidence interval [CI] ¼ 0.68 to 1.98, P ¼ .59), hospitalization status (HR ¼ 0.96, 95% CI ¼ 0.52 to 1.77, P ¼ .90), supplemental oxygenation (HR 1.14, 95% CI ¼ 0.66 to 1.99, P ¼ .64), and use of mechanical ventilation (HR ¼ 0.81, 95% CI ¼ 0.25 to 2.66, P ¼ .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor-directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor-directed therapy: HR ¼ 1.27, 95% CI ¼ 0.69 to 2.32, P ¼ .44). Conclusions: In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease.
Notes Role of the funder: The design, interpretation, and analysis of this study, the writing of the manuscript, and decision to submit the manuscript for publication rest solely with the authors.
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19-final report, N Engl J Med
Caffo, Zagonel, Baldessari, On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2, Ann Oncol
Chaipan, Kobasa, Bertram, Proteolytic activation of the 1918 influvirus hemagglutinin, J Virol
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Iwata-Yoshikawa, Okamura, Shimizu, Hasegawa, Takeda et al., TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection, J Virol
Klein, Li, Milinovich, Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2, J Urol
Koskinen, Carpen, Honkanen, Androgen deprivation and SARS-CoV-2 in men with prostate cancer, Ann Oncol
Kwon, Vashisht, Borno, Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry, Ann Oncol
Li, Han, Dai, Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide, Nat Commun
Lin, Ferguson, White, Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2, Cancer Res
Matsuyama, Nagata, Shirato, Kawase, Takeda et al., Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2, J Virol
Mikkonen, Pihlajamaa, Sahu, Zhang, Janne, Androgen receptor and androgen-dependent gene expression in lung, Mol Cell Endocrinol
Montopoli, Zumerle, Vettor, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n¼4532), Ann. Oncol
Mostaghel, Nelson, Lange, Targeted androgen pathway suppression in localized prostate cancer: a pilot study, J Clin Oncol
Patel, Zhong, Liaw, Does androgen deprivation therapy protect against severe complications from COVID-19?, Ann Oncol
Richardson, Hirsch, Narasimhan, the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Schmidt, Tucker, Bakouny, Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19, JAMA Netw Open
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit